Apatinib mesylate is a target therapy medication, developed and manufactured in China. In 2014, the results of the randomized phase III clinical trial were presented. The research was held in China. The patients were receiving Apatinib mesylate as the third line of therapy - a small molecule tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2). Compared to placebo, the medication has conclusively improved the survival index, with the acceptable tolerability levels.
Crizonix is a medicine used to treat cancer. Specifically, it is used to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or ROS 1 positive.
Cytoblastin (Vinblastine Sulphate) Intravenous Injection is indicated in the treatment of several different forms of cancer including Hodgkin`s disease, lymphocytic lymphoma, histiocytic lymphoma, mycosis fungoides, carcinoma of the testes, Kaposi`s sarcoma and Letterer-Siwe disease (histiocytosis X).
Gemoxen (Gemcitabine) is a cancer drug known as an antimetabolite indicated in the treatment of certain types of cancer, including ovarian cancer, pancreatic cancer, lung cancer, and breast cancer. Gemcitabine works by preventing certain proteins from being made that are necessary for growth of the cancer cells.
Mistletoe Extract is a phytotherapeutical product with good potential in the treatment in cancer patients. Mistletoe Extract may improve quality of life during chemotherapy and increase chances of survival in patients with cancer.
Pascorbin contains a high dosage of vitamin C (ascorbic acid) in an injectible solution. This form of vitamin C is used to treat psople who are not obtaining enough vitamin C through their diet, and who require a stronger dosage than oral vitamin C. Recently, there has been research into the positive effects that high-dose ascorbic acid injections can have on cancer patients.
Posid (Etoposide) is an oral cancer medication prescribed to treat patients suffering from lung cancer. It is commonly used in the event that other chemotherapy medicines have proven ineffective. The medication operates by preventing the spread and size increase of cancer cells by interfering with their growth.
Sorafenib (Sorafenat) is a kinase inhibitor used by patients suffering from hepatocellular carcinoma (a type of liver cancer), advanced renal cell carcinoma (a type of kidney cancer) and some cases of thyroid cancer.
Sunitix (Sunitinib) is used to treat patients with advanced kidney cancer, gastrointestinal stromal tumours (GISTs), or pancreatic neuroendocrine tumours. Sunitinib`s mechanism of action is to block the action of certain enzymes that are involved in growth of cancer cells. Sunitinib belongs to a group of medicines called protein kinase inhibitors.
Tagrix (Osimertinib) is prescribed to treat metastatic non-small cell lung cancer in patients with T790M mutation in the epidermal growth factor receptor (EGFR) gene, who developed progressive disease during and after EGFR tyrosine kinase inhibitor therapy.
Votrient is used to treat renal cell carcinoma or soft tissue sarcoma in patients who have already been treated with chemotherapy. Votrient contains the active ingredient Pazopanib and is classified as a tyrosine kinase inhibitor.
Zelgor (Abiraterone or Abiraterone Acetate) is a new medicine used toftreat men suffering from Metastatic Castration-Resistant Prostate Cancer (mCRPC). This is a form of prostate cancer that is resistant to hormonal or surgical treatment.
Zytix (Abiraterone Acetate) is used in cases of prostate cancer that have not been able to be treated by medical or surgical treatments and has spread to other parts of the body. Prednisone is always prescribed in combination with Zytix (Abiraterone Acetate).
Procalut is a brand of Bicalutumide. Procalut may be part of an overall treatment plan for males with prostate cancer. Procalut can help to block the androgens which can cause prostate tumors to grow and for prostate cancer cells to multiply. This is a medication for males only due to the way in which it affects hormones. It is classified as an anti-androgen.
Procur is a tablet form of Cyproterone Acetate. Each tablet contains 50mg of the active ingredient Cyproterone Acetate. Procur is a an antiandrogenic hormone medication with several different uses. It is indicated in the treatment of unoperable prostate cancer, hirsutism in women, to decrease excessive sex drive in males and as part of a transgender hormone therapy regimen.
Xgeva Injection (Denosumab) is a drug of human monoclonal antibodies (IgG2 isotype) produced on the cell line of mammals using recombinant DNA technology. Xgeva Injection (Denosumab) prescribed for prevention of bone pathologies in patients with metastatic bone defeat by solid tumors.
Zoladex 3.6mg Depot (Goserelin Acetate) is an antitumor hormone drug that is used in such cases as hormone-dependent prostate cancer, hormone-dependent breast cancer in women during the reproductive period or in perimenopause, endometriosis, uterine fibroids (in combination with surgical treatment), inhibition pituitary function in the preparation of stimulation of superovulation in the framework of the IVF program (in vitro fertilization), the need for preliminary thinning of the endometrium before surgery.
Zoladex LA Implant (Goserelin) is an anti-cancer medication prescribed for the treatment of prostate cancer. It has medicinal form of implant in pre-filled syringes. 1 implant contains goserelin acetate 12,50 mg in terms of goserelin 10,8 mg.
Imatib (Imatinib) is prescribed to treat patients suffering from certain types of leukemia such as Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) or Philadelphia chromosome positive chronic myeloid leukemia (CML).
Paclitaxel is a chemotherapy drug used in the treatment for many different types of cancer. Paclitaxel works by stopping cancer cells from separating into two new cells. This blocks the growth of the cancer.
Resihance (Regorafenib) is antineoplastic drug. It is a new option for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine, oxaliplatin and irinotecan, anti-VEGF drugs, and anti-EGFR therapy - in the case of wild-type KRAS and for the treatment of patients with inoperable or metastatic gastrointestinal stromal tumors (GIST) that previously received treatment with itiminib mesylate and sunnytinib malate. Resihance (Regorafenib) is also used to treat patients with hepatocellular carcinoma (HCC) who have previously received treatment with sorafenib.